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Abstract
Hyperbaric oxygen therapy (HBOT) is a clinical treatment in which a patient breathes pure
oxygen for a limited period of time at an increased pressure. Although this therapy has been
used for decades to assist wound healing, its efficacy for many conditions is unproven and
its mechanism of action is not yet fully clarified. This study investigated the effects of HBOT
on wound healing using a diabetes-impaired pressure ulcer rat model. Seven weeks after
streptozotocin-induced diabetes in rats (n = 55), a pressure ulcer was created on dorsal
skin. Subsequently, animals received HBOT during 6 weeks following a standard clinical
protocol (HBOT group with varying endpoints up to 42 days post-wounding) versus controls
without HBOT. Capillary venous oxygen saturation (SO2) showed a significant increase in
the HBOT group on day 24; however, this increase was significant at this time point only.
The quantity of hemoglobin in the micro-blood vessels (rHB) showed a significant decrease
in the HBOT group on days 21 and 42, and showed a trend to decrease on day 31. Blood
flow in the microcirculation showed a significant increase on days 17, 21 and 31 but a signifi-
cant decrease on days 24 and 28. Inflammation scoring showed significantly decreased
CD68 counts in the HBOT group on day 42, but not in the early stages of wound healing.
Animals in the HBOT group showed a trend for an increase in mean wound breaking
strength on day 42.
Introduction
The treatment of impaired wound healing remains a challenge. Various biological processes,
such as chronic inflammation, hampered keratinocyte functioning, and abnormalities in
growth factor production, extracellular matrix deposition and in the tissue remodeling pro-
cess, are proposed to contribute to compromised diabetes-impaired wound healing [1–4].
Hyperbaric oxygen therapy (HBOT) is a clinical treatment modality in which a patient
breathes pure oxygen while exposed to an increased atmospheric pressure of (generally) 2.4
atmospheres absolute (ATA) [5, 6]. HBOT is used to treat refractory diabetic wounds and
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reduce the risk of lower extremity amputation, with the aim to improve quality of life and
reduce the overall costs of care [7, 8].
The main mechanism of HBOT is thought to be related to the oxidative stress response
that improves neovascularization [6]. After HBOT, cells in the wound area exhibit increased
growth factor production and neovascularization, as well as improved cell migration and colla-
gen synthesis. A separate, free radical-based mechanism for the augmentation of neovasculari-
zation by HBOT is through circulating stem/progenitor cells (SPCs). Hyperoxia stimulates
mobilization of bone marrow SPCs and improves their function once they home to peripheral
sites [9].
Although HBOT is recommended in the treatment of diabetic wounds, its clinical effective-
ness remains unclear for many conditions. Moreover, in diabetic foot ulcers, HBOT increased
the rate of early ulcer healing but failed to provide a benefit in wound healing on long-term fol-
low-up [8]. Also, there is no evidence that HBOT promotes healing of venous, arterial and
pressure ulcers [8].
Studies on the efficacy and mechanisms of action of HBOT in a clinical setting have certain
limitations, whereas experimental animal models allow in-depth laboratory analysis. In the
present study, a standard clinical protocol was used: the animals receiving HBOT were
exposed to 100% oxygen for 1.5 h at 2.4 ATA, during weekdays for 6 weeks [6].
Our earlier study on the effects of 4 weeks HBOT in rats that were diabetic for one month,
showed improved oxygen saturation of the lower end of the capillary network together with
increased mean skin breaking strength; however, compared with controls, the difference did
not reach statistical significance [10].
The present study tests our hypothesis that HBOT delivers increased amounts of oxygen to
the wound area, leading to enhanced wound healing and improved tissue restoration. The effi-
cacy of HBOT was evaluated in pressure ulcers generated in rats that had untreated streptozo-
tocin (STZ)-induced diabetes for 7 weeks before wounding and HBOT. Effects of HBOT were
investigated up to 42 days post-wounding and consisted of evaluating the wound area, tissue
oxygen supply, vasodilatory capability, inflammation, neovascularization and tissue breaking
strength.
Materials and methods
Animals
WAG/RijHsd female rats (n = 55, 8 weeks old), SPF, were purchased from Charles-River
(L’Arbresle, France). The rats were housed with two animals per cage, exposed to a 12-h light/
dark cycle (lights on period: 7 AM-7 PM), at a temperature of 21–23˚C and fed with a standard
laboratory diet (Hope Farms, Woerden, the Netherlands) with food and water available ad libi-
tum. Cage enrichment was applied. During the experimental procedures, rats were inhalation-
anesthetized using 1.5% isoflurane (Pharmachemie BV, Haarlem, the Netherlands) in oxygen
as carrier.
The experimental protocol was approved by an Animal Experiments Committee (Stichting
Dec-Consult, the Netherlands), under the National Experiments on Animals Act and adhered
to the rules laid down in this national law that serves the implementation of Guidelines on the
Protection of Experimental Animals by the Council of Europe (1986), Directive 86/609/EC.
Induction of diabetes
After overnight fasting, rats were injected with STZ (Sigma-Aldrich, St. Louis, MO, USA),
intraperitoneal, at a dose of 60 mg/kg body weight in 0.05 mol/L sodium citrate buffer, pH 4.5.
Blood glucose was determined in the fed state at 9 AM (Zeitgeber time ZT2) using a OneTouch
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glucometer (LifeScan, Milpitas, CA, USA), twice weekly during the first 3 weeks, followed by a
weekly measurement. All animals had blood glucose levels 20 mmol/L throughout the
experimental period.
Ulceration model and HBOT
A total of 55 diabetic rats were ulcerated, on average 7 weeks after STZ injection. The ulcer is
created by clamping two-magnet-disk (15 mm diameter each) on the dorsal skin of the rat.
The clamping duration (ischemic period) is 16 h, which created two 15-mm diameter ulcera-
tion wounds. During the ischemic period and for three days post-clamping the rats received
analgesia (Temgesic 0.5 mg/kg; Reckitt Benkiser Pharmaceuticals, Berkshire, UK).
After the ischemic period animals were randomly divided into three groups: Group 1,
endpoint day 7 (n = 18); Group 2, endpoint day 14 (n = 18); and Group 3, endpoint day 42
(n = 19). Within each group the animals were divided into the HBO-treated group and the
control group, all having comparable glucose levels and body weight. HBO-treated rats were
given 100% oxygen under a pressure of 2.4 ATA for 90 min, using a custom designed hyper-
baric oxygen tank (IHC High Tech, Raamsdonkveer, the Netherlands) suitable for animals
[11]. Non-HBOT (control) rats experienced similar handling and similar machine noise as the
HBOT animals, but breathed normoxia at sea level pressure.
Macroscopic analysis
Body weight measurement and ulcer photography were performed weekly. A ruler was placed
next to the wound as calibration for further analyses. The macroscopic wound areas were cal-
culated using ImageJ (National Institutes of Health, Bethesda, Maryland, USA).
Sampling and preparation
When reaching their respective experimental endpoints, the rats were anesthetized and eutha-
nized by thoracic bleeding. For rats assigned for breaking strength measurements, the dorsal
pelt was excised. For all other rats, the ulcer tissues, including 2 mm of the surrounding normal
skin, was excised and cut into halves. One half was fixed in 10% phosphate-buffered formalin
for histology and immunohistochemistry. From the other half of the wound, the surrounding
normal skin tissue was excised and the wounded tissue was snap-frozen in liquid nitrogen and
homogenized using a Mikro-Dismembrator (B. Braun Biotech International, Melsungen,
Germany).
Breaking strength measurements
Breaking strength was measured as described previously [12]. In brief, the skin containing the
wound area was excised and cut into an hour glass-shaped strip with standard dimensions of 4
x 45 mm. The strips were lengthwise positioned in a 10-kg force transducer that is part of a
Testometric1 AX, M250-2.5KN tensiometer (Testometric Co. Ltd, Lancashire, UK). Breaking
strength is measured by determining the failure force of the skin strip.
Immunohistochemistry
To evaluate inflammation and angiogenesis in the ulcer tissue, CD68 (a monocyte/macro-
phage marker, purchased from AbD Serotec, Du¨sseldorf, Germany), CD34 (an endothelial cell
marker, purchased from R&D Systems, Minneapolis, MN, USA) and a vascular endothelial
growth factor (VEGF; purchased from AbD Serotec, Du¨sseldorf, Germany) were used, respec-
tively, and detected using immunohistochemistry (ABC complex), as described previously
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[13]. Stained and mounted sections of HE, CD34 and CD68 were scanned for virtual micros-
copy at 40x magnification, using a Hamamatsu Nanozoomer 2.0-HT robot (Hamamatsu Pho-
tonics K.K., Hamamatsu City, Japan). Subsequently, using virtual microscopy software NDP
(Hamamatsu), JPEG images of all sections except HE, were taken at 2.5X magnification (10x
digital zoom) and loaded into CellD software (Olympus, Hamburg, Germany) for computer-
ized quantitative analysis. Thresholds for number of pixels, hue, saturation, and intensity were
set and verified by human eye. Either percentage staining of the total area (CD34, CD68) or
the absolute dermal thickness was calculated.
Vasodilatory capability measurements
Laser Doppler Flowmetry (LDF) with local heat provocation measures the vasodilatory capa-
bilities of the wounded skin following super physiological local heating to 44˚C. The microcir-
culatory response to this local heating was performed at day 42, the end point of the study, and
monitored as described in detail previously [12].
Tissue oxygen supply
Oxygen supply in the microcirculation was measured using an O2C Laser Doppler Flow meter
and tissue spectrometer (LEA Medizintechnik Giessen, Germany). Oxygen saturation of
hemoglobin (SO2), was measured at the venous end of the capillaries; this point represents the
lowest oxygen saturation of the tissue. The relative amount of hemoglobin (rHB) represents
the quantity of hemoglobin in the micro-blood vessels and, therefore, reflects the density of
the blood vessels [14].
Statistical analysis
Analyses were performed with IBM SPSS software, version 21 (Chicago, IL, USA). An inde-
pendent samples t-test was used to compare results between the two groups. Two-sided p-
values 0.05 were considered to indicate statistically significant differences. Treatment differ-
ences over time were analyzed using a model of general linear repeated measures. Data are pre-
sented as means ± SEM.
Results
Diabetes induction and glucose levels
Female WAG/RijHsd rats (n = 55), on average 8 weeks old and with an average weight of
134.4 ± 7.9 g, were used in the study. Following STZ injection, all rats became hyperglycemic:
50 rats had blood glucose levels > 19 mmol/L in the period after the STZ injection until their
experimental endpoint. In five rats the blood glucose levels gradually dropped towards the end
of the experiment; however, these animals still had blood glucose levels > 10 mmol/L at all
times during their experimental period. In four rats, blood glucose levels dropped to normo-
glycemia in the diabetes induction period; these animals were reinjected with STZ and then
maintained glucose levels of>20 mM during the remainder of the study protocol.
All 55 rats showed similar behavior and were included in the analysis. No significant differ-
ences in mean blood glucose level were observed between the two groups during the treatment
period.
Effect of diabetes and HBOT on body weight
The average loss of body weight during the first week after STZ injection was 4% (average
weight 130 g). At the end of the diabetes induction phase (week 7) the average body weight
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had increased to 104% of the starting weight (average weight 140 g) with no significant differ-
ences between the groups assigned to the subsequent HBOT or control treatment.
Analysis of the body weight data during the experimental phase on a per-group basis
showed no significant differences in body weight between the HBOT and control groups that
had their experimental endpoint on day 7 and day 14.
On an average of 7 weeks after diabetes induction, two pressure ulcer wounds were created
on the dorsal skin of each animal. During the wound-healing phase, HBOT rats showed a sig-
nificantly increased body weight in experimental week 4 (HBOT 146 ± 3 vs. control 136 ± 2 g;
95% confidence interval [CI] 3–18 g; p = 0.009) and in experimental week 5 (HBOT 149 ± 3
vs. control 141±2 g; 95% CI 1–14 g; p = 0.026).
Effects of HBOT on wound area reduction
Fig 1A shows that the reduction in the mean wound area was delayed in the HBOT group on
day 10 post-wounding compared to the control group; however, this difference was not signifi-
cant (67.9 ± 4.4% versus 60.9 ± 3.4%; p< 0.23). On experimental day 16, the mean wound
Fig 1. Effect of HBOT on wound area reduction. A. The effect of HBOT on wound area reduction was
measured using ImageJ. The measured wound area at day 0 was set to 100%. Data are presented as
mean ± SEM. *p < 0.05 indicates a significant difference between the HBOT and control group. B.
Representative macroscopic images of wounds from HBOT and control animals on experimental days 0, 7,
10, 16, 20 and 23.
https://doi.org/10.1371/journal.pone.0177766.g001
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area in the HBOT group was reduced to 7.4 ± 1.3% vs. 13.4 ± 3.3% in the control group
(p< 0.09) and reached a significant reduction on experimental day 20 (HBOT 0.4 ± 0.2% vs.
control 3.1 ± 1.1%; 95% CI 0.3–5.1%; p = 0.028). However, analysis of the treatment effects
over time (day 0 to day 23) showed no significant difference in wound area reduction between
the two groups. Representative images of the wounds are presented in Fig 1B.
Tissue oxygen supply
Tissue oxygen levels were determined in the HBOT and control groups at multiple time points
and started on day 17 post-wounding, i.e. the moment when the eschar had detached from all
wounds.
The capillary-venous oxygen saturation (SO2) (Fig 2A), the relative amount of hemoglobin
(rHB) (Fig 2B), and blood flow in the microcirculation (Fig 2C) were determined. To correct
data for possible between-animal variation in tissue architecture and vascular characteristics,
oxygen supply was measured in the wounds and normal skin of the same animal. Fig 2 pres-
ents the values in the wound as a percentage of skin perfusion in non-wounded skin.
Capillary-venous oxygen saturation showed no difference between the two groups except
on day 24, when the SO2 ratio was increased two-fold in HBOT animals as compared to con-
trol animals (2.86 ± 0.24 in the HBOT group vs. 1.42 ± 0.14 in the control group; 95% CI 0.87–
2.01; p = 0.000) (Fig 2A). No explanation could be found for this significant difference at this
single time point. Analysis of the treatment effects over time (day 7 to day 42) showed no sig-
nificant difference in tissue oxygen supply between the two groups.
The quantity of hemoglobin in the micro-blood vessels (rHB) showed a significant decrease
in the HBOT group on day 24 (1.14 ± 0.05 in the HBOT group vs.1.64 ± 0.12 in the control
group; 95% CI 0.25–0.75; p = 0.000) and on day 42 (1.46 ± 0.07 in the HBOT group vs. 1.83 ±
0.08 in the control group; 95% CI 0.16–0.57; p = 0.001) but showed a significant increase on
day 31 in this group (1.69 ± 0.10 in the HBOT group vs. 1.35 ± 0.1 in the control group; 95%
CI 0.67–0.004; p = 0,048) (Fig 2B).
Flow in the microcirculation showed a significant increase in the HBOT group on day 17
(2.74 ± 0.26 in the HBOT group vs. 1.96 ± 0.26 in the control group; 95% CI 1.53–0.04;
p = 0.04) and day 21 (2.37 ± 0.23 in the HBOT group vs. 1.75 ± 0.15 in the control group; 95%
CI 1.18–0.05; p = 0.03), a significant decrease on day 24 (1.12 ± 0.09 in the HBOT group vs.
1.43 ± 0.12 in the control group; 95% CI 0.62–0.00; p = 0.05) and day 28 (0.94 ± 0.08 in the
HBOT group vs. 1.27 ± 0.10 in the control group; 95% CI 0.59–0.07, p = 0.01), and increased
again on day 31 (1.33 ± 0.16 in the HBOT group vs. 0.85 ± 0.07 in the control group; 95% CI
0.83–0.13, p = 0.03) (Fig 2C).
Effects of HBOT on granulation tissue deposition
The formation of granulation tissue (or neo-dermis) was measured on hematoxylin and eosin
(H&E) stained sections on all experimental end points. HBOT caused a significant increase
in granulation tissue deposition in the wound area on day 7 (0.69 ± 0.04 mm in the HBOT
group vs. 0.58 ± 0.04 mm in controls, 95% CI -0.22 to 0.00 mm; p = 0.04). However, on day 14,
the neo-dermal thickness of the wounds in the control group showed a significant increase
(0.78 ± 0.05 in the HBOT group vs. 0.95 ± 0.04 mm in the control group, 95% CI 0.04–0.31
mm; p = 0.01), whereas on day 42 no significant differences were observed between the two
groups (Fig 3A). Epidermal measurements in the wound area showed no significant difference
between the HBOT and control group. Representative images of the wound histology are pre-
sented in Fig 3B.
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Effects of HBOT on inflammation
Inflammation was evaluated by determining the abundance of monocytes/macrophages in the
wounds using an anti-CD68 antibody. Representative immunohistochemical images are pre-
sented in Fig 4B. As shown in Fig 4A, on day 42 the score of CD68 staining was significantly
reduced in the HBOT wounds (4.18 ± 0.83 in the HBOT group vs. 6.39 ± 0.49 in the controls,
95% CI 0.96–4.33; p = 0.04). However, analysis of the treatment effects over time (day 7 to day
42) showed no significant difference in the abundance of monocytes/macrophages in the
wounds between the two groups.
Fig 2. Effect of HBOT on wound tissue perfusion. A. Effect of HBOT on hemoglobin oxygen saturation
at the venous end of the capillaries (SO2) Oxygen saturation in the wounded and normal skin was measured
in the HBOT and control animals (20 h post-HBOT). Oxygen saturation in the wound is expressed as a
percentage of the flow in the normal skin of the same animal. B. Effect of HBOT on quantity of hemoglobin.
Quantity of hemoglobin in the wounded and normal skin was measured in the HBOT and control animals (20 h
post-HBOT). Quantity of hemoglobin in the wound is expressed as a percentage of the flow in the normal skin
of the same animal. C. Effect of HBOT on blood flow. Blood flow in the wounded and normal skin was
measured in the HBOT and control animals (20 h post-HBOT). Blood flow in the wound is expressed as a
percentage of flow in the normal skin of the same animal. Data are shown as means ± SEM. *p 0.05,
**p 0.01 and ***p 0.001 indicate significant differences between the HBOT and control group.
https://doi.org/10.1371/journal.pone.0177766.g002
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Effects of HBOT on vascularization
Vascularization was visualized by immunostaining the endothelial cells in the wound tissue
using the endothelial cell marker CD34. The morphology of CD34 positive endothelial cells
could easily be discriminated from residual hematopoietic stem cells. No significantly different
vascularization could be observed between the HBOT and control group although a trend
towards increased vascularization by HBOT could be observed at days 14 (HBOT 1.01±0.08
vs. controls 0.84±0.08, 95% CI -0.39 to 0.06; p = 0.14) and 42 (HBOT 0.77±0.14 vs. controls
0.53±0.05, 95% CI -0.57 to 0.08; p = 0.12) (Fig 5A). Representative immunohistochemical
images are presented in Fig 5B.
Fig 3. A. Effect of HBOT on formation of granulation tissue. The effect of HBOT on the formation of
granulation tissue (or neo-dermis) was assessed by H&E stained histology and CellD measurement at the
experimental endpoints. Data are presented as mean ± SEM. *p 0.05, and **p 0.01 indicate significant
differences between the HBOT and control group. B. Representative images of the wound histology of HBOT
and control groups on experimental days 7, 14 and 42. Scale bar: 500 μm.
https://doi.org/10.1371/journal.pone.0177766.g003
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Effects of HBOT on vasodilatory response to local heating
At the experimental endpoint at day 42, the wounds were monitored for their vasodilatory
response to super-physiological local heating using LDF. No differences in excess heat pro-
voked perfusion characteristics were observed between the HBOT and control groups (per-
centage baseline change HBOT 19.1 ± 5.8% vs. control 17.3 ± 5.4%; p = 0.84) (Fig 6A).
Fig 4. A. Effect of HBOT on inflammation reduction. The effect of HBOT on the inflammatory cell influx
was evaluated by quantitating the immunohistochemical stain of the monocyte/macrophage marker CD68.
Data are presented as mean ± SEM. *p0.05 indicates a significant difference in inflammatory response
between the HBOT and control group.B. Representative images of CD68 wound immunohistochemistry of
HBOT and control animals on experimental days 7, 14 and 42. Scale bar: 500 μm. Scale bar 40x insert:
50 μm.
https://doi.org/10.1371/journal.pone.0177766.g004
HBOT and diabetes impaired wounds
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Effects of HBOT on tissue breaking strength
At the experimental endpoint on day 42, HBOT showed no significant effect on the breaking
strength of wounded skin (20.0 ± 1.2 N in the HBOT group vs. 17.3 ± 1.2 N in the control
group; NS) and unwounded skin (34.6 ± 1.4 in the HBOT group vs. 36.7 ± 1.0 in the controls;
NS). However, when the breaking strength of the wounded tissue was expressed as a percent-
age of the strength of the surrounding unwounded skin, the HBOT showed an increased mean
value (0.58 ± 0.04 of normal skin in the HBOT group vs. 0.48 ± 0.04 in the control group, 95%
CI -0.21 to 0; p = 0.065) (Fig 6B).
Fig 5. A. No significant effect of HBOT on enhancing vascularization. The effect of HBOT on the
process of vascularization was evaluated by the immunohistochemical stain of the endothelial cell marker
CD34. Data are presented as mean ± SEM. B. Representative images of CD34 wound immunohistochemistry
of HBOT and control animals on experimental days 7, 14 and 42. Scale bar: 500 μm. Scale bar 40x insert:
50 μm.
https://doi.org/10.1371/journal.pone.0177766.g005
HBOT and diabetes impaired wounds
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Discussion
The treatment of diabetic ulcers requires a multifactorial approach due to the multifactorial
etiology of diabetic ulcers [15]. The approach includes an extensive debridement, off-loading
of areas with high pressure, control of metabolism and concomitant diseases, ulcer care, and
the education of care. However, despite applying all conventional treatment methods, the
treatment of diabetic ulcers often fails to match the expectations of healthcare professionals.
Then, adjunctive therapies, such as topically and systemically applied growth factors, bioengi-
neered biological coverings, and HBOT, are considered. However, evidence for the effective-
ness of most of these therapies, including HBOT, is scarce [8, 16].
Fig 6. A. Effect of HBOT on the vasodilatory response to super-physiological local heating on day
42 post-wounding. The vasodilatory response to local heating (44˚C for 10 min) was measured in the
wounds of HBOT and control animals by laser doppler flowmetry. The vasodilatory response in the wound
tissue is expressed as the increase in blood flow over baseline flow. B. Ratio of the skin breaking strength
of normal and wounded skin in diabetic rats on day 42 post-wounding. Breaking strength of the wounded
skin is depicted as a percentage of the breaking strength of the normal skin in the same animal. The wounded
skin versus normal skin ratio was calculated for the HBOT and control group on day 42. Data are presented as
mean ± SEM.
https://doi.org/10.1371/journal.pone.0177766.g006
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As an adjunctive treatment of diabetic ulcers HBOT has been used for over 40 years, but
its efficacy remains controversial. Due to the limited evidence in randomized controlled trials
(RCTs), it is difficult to conclusively support or reject the benefits of HBOT in treating diabetic
ulcers [17–20]. No significant effects on amputation rates have been found in RCTs evaluating
HBOT (19). For diabetic foot ulcer healing, although positive results have been reported [7, 8,
21, 22], the rationale behind the observed effect is sometimes unclear. For example, in the RCT
of Londahl et al. [22], a significant effect of HBOT on ulcer size reduction was observed only
from experimental month 9 onwards; this is 7 months after the last HBOT session. In another
study, a period of almost 1 year between cessation of HBOT and a significant effect was reported
[23]. To elucidate the effects of HBOT, insight into several parameters and tissue response is
needed that, for ethical reasons, cannot easily be achieved in studies among patients.
In the present study, a STZ-induced diabetic rat model of ischemia-reperfusion injury-
induced pressure ulcers was used in which the healing time of magnet compression-induced
ulcers was delayed by over 50% [13, 24]. The HBOT protocol used in the present study follows
standard clinical practice. The outcomes of wound closure, tissue oxygen supply, vasodilatory
capability, inflammation, neovascularization, and tissue breaking strength, were evaluated;
however, most of the results obtained are not straightforward.
The magnet clamping ulceration model creates extensive vascular damage. All blood vessels
beneath the magnet compression area become necrotic, which calls for extensive neovasculari-
zation. Achieving increased neovascularization is an important rationale for using HBOT [23,
25]. In our animal model, neovascularization in ulcer tissue was found to be increased after
HBOT at the early stage of wound healing. HBOT also stimulated granulation tissue formation
on day 7; however, this effect was reversed on day 14. Neovascularization is involved in both
angiogenesis and vasculogenesis. Regional growth factors stimulate the former, and recruit-
ment and differentiation of circulating SPCs stimulate the latter. In the present study, the
production of growth factors such as VEGF (the most specific growth factor for neovasculari-
zation) was not enhanced (data not shown). Therefore, the mechanism of action of HBOT in
increasing neovascularization is probably not directly related to angiogenesis.
In the literature, two potentially additive mechanisms of HBOT action have been proposed.
1. HBOT transports oxygen to bodily sites where vascularization is poor or absent, such as
in poorly healing wounds. This proposed mechanism of HBOT action relates to the physical
relationship between pressure and gas concentration in a liquid [26]. It is known that 2.4 ATA
of pure oxygen dissolves a substantial amount of oxygen in blood plasma. In the late 1950s,
Boerema et al. showed that phlebotomized dogs could survive in HBOT conditions [27].
2. Cyclic periods of hyperbaric oxygen and normoxic oxygen create a stress response by
repeatedly increasing and decreasing the number of reactive oxygen species (ROS) in the tis-
sues. ROS influence the signal transduction pathways of multiple growth factors, including
those implicated in propagating angiogenesis. Thom (2011) published a concise review on this
topic [6].
Both proposed mechanisms are also likely to play a role in delayed healing of lower extrem-
ity wounds and in our ischemia ulceration model in diabetic animals.
In the present study, no effect of HBOT on vasodilatory capability in ulcer tissue was
observed. This is in contrast to our earlier work using a similar animal model in which we
measured perfusion parameters on day 29 only [10]; in that study, because flow was restricted,
and SO2 and rHB increased in HBOT animals, this suggested that HBOT induced vasocon-
striction and improved tissue perfusion at the lower end of the capillary system. In the present
study, on experimental day 28, these latter findings were not confirmed, i.e. in the present
study, the overall effects of HBOT on tissue perfusion showed no significant differences over
time when analyzed using a general linear repeated measures model.
HBOT and diabetes impaired wounds
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SO2 values, measuring capillary venous oxygen saturation, showed a significant increase in
the HBOT group only at a single time point, whereas rHB values showed a significant decrease
in wounds of HBOT animals at several time points. Blood flow in the lower end of the capillary
system was increased in 3 of the 6 time points but showed a significant decrease at the remain-
ing two time points.
As HBOT has only a temporary effect on increasing tissue oxygenation, it could be argued
that we missed these early effects on tissue oxygenation by performing measurements on the
following morning, i.e. 8–20 h after the previous HBOT session had ended. Although this is a
valid point, we deliberately avoided perfusion measurements immediately following HBOT as
our pilot experiments showed substantial differences between animals, that seemed mainly
attributable to the time that the measurements were made post-HBOT. Perfusion measure-
ments take 5–10 min per animal. Therefore, the time post-HBOT varies considerably between
the first and last animal when measurements start directly start after cessation of the HBOT
session.
Another drawback of the perfusion measurements we performed is that we can only mea-
sure erythrocyte coupled oxygenation, and dispersion and speed of erythrocytes through the
tissue. In view of the proposed mechanism of action of HBOT, i.e. dissolving oxygen under
pressure in blood plasma brings oxygen (through plasma extravasation) from the small vascu-
lature to bodily sites distant from vascularization, our perfusion measurements are not able to
measure this. Real-time monitoring of oxygen levels in tissues of living animals on a 24-h basis
is not possible, considering the large number of animals we included.
Therefore, an important aspect of HBOT, namely neovascularization to restore adequate
blood flow, is not proven in this animal model. However, it has been demonstrated that HBOT
induces angiogenesis and promotes neovascularization in wounds [28].
Excess inflammation and infection are consistent features of diabetes-impaired wound
healing [29]. In this ischemia-reperfusion injury model, throughout reperfusion, leukocytes
(after adhering to ischemic tissues) cause pathologic vasoconstriction and tissue damage by
releasing proteases and free radicals [29]. In this study, the decreased dermal thickness (ob-
served in the HBOT group on day 14) may reflect a more advanced wound healing in this
group. Our inflammation data, slightly reduced on day 14 and significantly reduced on day
42, may also contribute to this view of advanced wound healing in HBOT animals, as it is
tempting to speculate about an increased inflammation resolution in this group. The effects of
HBOT on improvement of wound healing, together with resolution of inflammation, were
also observed in our previous studies using this ulceration model, in which a heparin sulfate
analogue was tested [24, 30]. Inflammation resolution one of the mechanisms by which HBOT
may improve impaired wound healing. In addition, advancement of wound healing is also
reflected in blood vessel condensation. Therefore, one might speculate a slight decrease in tis-
sue perfusion in the HBOT group on day 14. However, crust formation precluded reliable SO2
and rHB measurements during the first two weeks of wound healing. On day 17, by which
time the crust was detached from the wound in all animals, no significant differences were
found in tissue saturation.
Collagen deposition and reorganization indicate the quality of wound healing [31]. Colla-
gen deposition starts with procollagen synthesis. Subsequently, this procollagen is converted
to collagen, and cross-linked to form a collagen matrix; this process is oxygen-dependent. In
animal experiments, collagen deposition in a hyperoxic environment increased 3-fold com-
pared with deposition in a hypoxic environment [32]. Improved ulcer breaking strength (bio-
mechanical strength) is a powerful outcome of collagen biosynthesis, especially of cross-linked
collagen biosynthesis. In the present study, the ulcer breaking strength showed a strong trend
towards improvement following HBOT, as was also reported by Tuk et al. [10].
HBOT and diabetes impaired wounds
PLOS ONE | https://doi.org/10.1371/journal.pone.0177766 May 17, 2017 13 / 16
A limitation of the present study is that only female WAG/RijHsd rats were used; this
implies that our findings may not be generalized to male rats or other rat strains.
In summary, not all evidence obtained from this animal model supports the hypothesis that
HBOT has a positive effect on wound healing. Nevertheless, these data indicate that HBOT
almost significantly improves tissue strength, and may have some effect on neovascularization
at the later stages of wound healing.
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